Yunnan To Pump RMB 82.6 Billion Into Biopharma Industry In 12th Five-Year Plan
This article was originally published in PharmAsia News
The Yunnan government will invest RMB 82.6 billion into the province's biopharmaceutical industry during the 12 Five-Year Plan period, according to Yunnan authorities
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.